乳腺癌脉管标记物的临床应用与研究进展  

Clinical application and research progress of lymphovascular markers for breast cancer

作　　者：张宇飏 王洪江[1] ZHANG Yuyang;WANG Hongjiang(Department of Breast Surgery,First Affiliated Hospital of Dalian Medical University,Dalian,Liaoning 116044,China)

机构地区：[1]大连医科大学附属第一医院乳腺外科,辽宁大连116044

出　　处：《中国临床研究》2024年第3期329-333,共5页Chinese Journal of Clinical Research

基　　金：国家自然科学基金(81572582)。

摘　　要：乳腺癌已成为目前女性发病率最高的恶性肿瘤,其诊疗原则主要依赖于传统的组织学和分子学病理特征。然而,乳腺癌的全身性转移始于癌细胞侵入原发肿瘤部位及其周围的血管和淋巴管。病理学家通过免疫组织化学技术和脉管内皮标记技术的结合,得以区分淋巴管与血管侵袭,并认识到淋巴管内皮细胞及血管内皮细胞在肿瘤进展及转移中的作用。本文归纳了近年乳腺癌特异性脉管内皮标记物的相关临床研究进展及应用,以期为进一步揭示乳腺癌的进展机制、探索其新的预后指标和治疗靶点提供思路。Breast cancer has become the most common malignant tumor in women,and its diagnosis and treatment principles mainly depend on the traditional histological and molecular pathological features.However,the systemic metastasis of breast cancer begins when cancer cells invade the primary tumor site as well as surrounding blood and lymphatic vessels.Pathologists have been able to distinguish between lymphatic and vascular invasion through a combination of immunohistochemical and vascular endothelial labelling techniques,and have recognized the role of lymphatic endothelial cells and vascular endothelial cells in tumor progression and metastasis.This paper summarizes the relevant clinical research progress and application of specific lymphovascular endothelial markers in breast cancer in recent years,in order to provide ideas for further revealing the progress mechanism of breast cancer and exploring new prognostic indicators and therapeutic targets for breast cancer.

关 键 词：乳腺癌 脉管内皮标记物 脉管癌栓 淋巴管生成 血管生成 平足蛋白 血小板内皮细胞黏附分子 内皮糖蛋白 血管内皮生长因子受体 趋化因子受体 

分 类 号：R737.9[医药卫生—肿瘤]